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ABSTRACT 
Background: The irritable bowel syndrome (IBS) is one of the most prevalent 
disorders and affects about 15% of the Swedish population. Patients with IBS 
suffer from abdominal pain and disturbed bowel function. Despite being so 
common, little is known about causality in IBS. Patients with IBS have been 
found to exhibit low-grade inflammation of nerve plexuses in the gut. The 
driving force for observed immune activation is yet unknown.  
Aim of the thesis: To assess if bacteria may have a role in the pathogenesis of 
IBS. This was addressed using different models. The first was to investigate if 
Chlamydia antigens were present in the small bowel of patients with severe 
IBS. Then the interaction between Chlamydia and enteroendocrine cells (EEC) 
in vitro using enteroendocrine cell lines was studied and finally the 
composition of small bowel mucosa-associated microbiota was explored in 
patients with IBS and healthy controls using pyrotag sequencing. 
Material and methods:  In Study I full-thickness jejunum biopsies and 
mucosa biopsies from the duodenum and the jejunum from patients with severe 
IBS and healthy controls were investigated with immunofluorescence for 
chlamydial antigens. In studies II and III two different human enteroendocrine 
cell lines were studied: LCC-18 from a neuroendocrine colonic tumour and 
CNDT-2 from a small intestinal carcinoid. Cell lines were infected with C. 
trachomatis serovar LGV II strain 434.  Penicillin G was used for inducing 
persistent infection. The ultrastructure of infected cells was studied using 
transmission electron microscopy and immunofluorescence and we used RT-
PCR analysis and microarray analysis (Affymetrix GeneChip®) for studying 
changes in gene expression at different stages of infection. In Study IV capsule 
biopsies from the jejunum of patients with IBS and healthy volunteers were 
studied using barcoded 454-pyrosequencing to determine the composition of 
microbial communities in the upper small bowel.  
Results: Chlamydia LPS was detected in enteroendocrine cells of the mucosa 
or subepithelial macrophages in 89% of patients with IBS, but in only 14% of 
healthy controls (p < 0.001) and 79% of LPS-positive biopsies were also 
positive for C. trachomatis major outer membrane protein. The cell line 
experiments showed that both cell lines could be infected with C. trachomatis 
yielding productive infection and persistence could be induced using penicillin 
G. The cellular distribution of serotonin and chromogranin A was altered by 
infection from a cytoplasmatic distribution to a location mostly in chlamydial 
inclusions. Significant differences in the gene transcription levels between 
persistently infected and non-infected cells were found in 10 genes coding for 
different solute carrier transporters (SLC) and 5 genes related to endocrine 
function (GABARAPL1, GRIP1, DRD2, SYT5 and SYT7). Study IV showed 
no major difference in small bowel mucosa-associated microbiota between 
patients with IBS and healthy controls. 
Conclusions: Study I introduced the novel concept that infection with C. 
trachomatis might be involved in the pathogenesis of IBS. In vitro studies 
confirmed that such an infection affects enteroendocrine cell function. The 
luminal flora of the small bowel was not identified as a host factor for 
developing IBS.  
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1 INTRODUCTION 
Disorders of gut function are among the most prevalent problems presented to 
gastroenterologists of the Western world and irritable bowel syndrome (IBS) is the 
most common functional gastrointestinal disorder (1). Although IBS is not a life-
threatening disease, the chronic nature of IBS tends to interfere with the normal daily 
life and IBS can have a strong impact on the patient’s quality of life (2, 3). Patients with 
IBS and co-morbid somatic disorders report more severe IBS symptoms and low 
health-related quality of life. IBS has been associated with fibromyalgia, chronic 
fatigue syndrome, temporo-mandibular joint disorder and chronic pelvic pain (4). In 
addition to individual patient discomfort, the costs related to IBS are substantial. In the 
United States, the total costs associated with IBS include $10 billion in direct medical 
costs and $20 billon in indirect costs, such as absence from work and loss of 
productivity (5). 
 
1.1 THE ROME CRITERIA FOR FUNCTIONAL GASTROINTESTINAL 
DISORDERS 
IBS is a syndrome, i.e. defined by the presence of certain symptoms. Thus defined, IBS 
seems to be a rather heterogeneous disorder with multiple presentations, possibly of 
different origins (6). In order to improve diagnosis and management, patients with IBS 
were classified into different groups according to their predominant symptoms (7). The 
development of symptom criteria for IBS has been an iterative process over the last 20 
years. 
 
1.1.1 Rome-I criteria for IBS  
At least 3 months of continuous or recurrent symptoms of: 
1. abdominal pain or discomfort which is 
a. relieved with defecation 
b. and/or associated with a change in frequency of stools 
c. and/or associated with a change in the consistency of stools 
and 
2. Two or more of the following are present at least 25 percent of occasions or days: 
a. altered stool frequency  
b. altered stool form (lumpy/hard or loose/watery stools)  
c. altered stool passage (e.g. sensations of incomplete evacuation, straining, or urgency) 
d. passage of mucus 
e. bloating or feeling of abdominal distention (8) 
 
1.1.2 Rome-II criteria for IBS  
At least 12 weeks, which need not be consecutive, in the preceding 12 months of 
abdominal discomfort or pain that has 2 out of 3 features: 
1. Relieved by defecation 
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2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool (9). 
 
1.1.3 Rome-III criteria for IBS 
Recurrent abdominal pain or discomfort at least 3 days per month associated with 2 or 
more of the following: 
1. Improvement with defecation.  
2. Onset associated with a change in frequency of stool  
3. Onset associated with a change in the appearance of stool. 
Start of symptoms at least 6 months previously (10). 
 
1.2 IBS – DEFINITION 
All studies concerning patients utilized the Rome-II criteria for IBS. Patients were 
diagnosed by experienced specialists in gastroenterology. The Rome-II diagnostic 
criteria define IBS by the presence of recurrent abdominal pain or discomfort for at 
least 12 weeks, that need not be consecutive, during the last 12 months associated with 
two or more of the following: improvement with defecation, onset associated with a 
change in frequency of stool, or onset associated with a change in form (appearance) of 
stool. Additional symptoms that are not part of the diagnostic criteria cumulatively 
support the diagnosis of IBS: abnormal stool frequency; abnormal stool form; abnormal 
stool passage; passage of mucus; and bloating or feeling of abdominal distension (9).  
 
1.3 IBS – SUBTYPES 
The latest Rome III criteria subtype patients exclusively according to their stool form 
because it better reflects transit time: 
1. IBS with constipation (IBS-C): hard or lumpy stools more than 25% of the time and 
loose/watery stools appearing in fewer then 25% of bowel movements. 
2. IBS with diarrhoea (IBS-D): loose/watery stools more than 25% of the time and hard 
or lumpy stool appearing in fewer than 25% of bowel movements. 
3. Mixed IBS (IBS-M): hard or lumpy stools more than 25% of the time and 
loose/watery stools in more than 25% of bowel movements. 
4. Unsubtyped IBS: insufficient abnormality of stool consistency to meet criteria for 
IBS-C, IBS-D, or IBS-M. IBS-C, -D and -M subtypes are believed to have a similar 
distribution, each accounting for approximately 30% of cases (11, 12).  
 
Rome-II criteria identify diarrhoea-predominant IBS (D-IBS) and constipation-
predominant IBS (C-IBS) (9). Patients who fulfil the symptom criteria for IBS but not 
for any of the two subtypes are sometimes referred to as A-IBS (alternating stool 
pattern) or M-IBS (mixed stool pattern IBS). 
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1.4 IBS – PREVALENCE 
Estimates of the prevalence of IBS vary across studies between 5-20% of the 
population of most countries with peaks in the third and fourth decades (13, 14). IBS is 
more common in women. In the community, the ratio of women to men with IBS is 
about 2:1, and the difference is even greater in the health care-seeking population, with 
women leading men by up to 4:1 (15). Female patients report greater overall IBS 
symptom severity, intensity of abdominal pain and bloating, and impact of symptoms 
on daily life, and lower health-related quality of life than male patients. The reason for 
this is not fully understood, but women also report more extraintestinal symptoms, such 
as nausea and urinary urgency. IBS symptoms in women vary according to the 
menstrual cycle, with increased symptoms just before and during the menses (15). 
 
1.5 IBS – PATHOPHYSIOLOGY 
The pathophysiology of IBS is still not well understood. Several mechanisms have been 
proposed, including psychological disturbances, abnormal gastrointestinal motility, 
visceral hyperalgesia, altered central perception of visceral events and hypothalamic-
pituitary axis dysfunction (16). Recent studies have focused on low-grade inflammation 
and dysregulation of intestinal microflora (17-19). 
 
1.5.1 Post-infectious IBS 
Studies have repeatedly found that IBS can arise after an acute gastroenteritis. This 
phenomenon, known as post-infectious IBS (PI-IBS) denotes the persistence of 
abdominal discomfort, bloating and diarrhoea that continues despite clearance of the 
inciting pathogen (20). Probably the first consistent report on PI-IBS dates back to the 
beginning of the century when Sir Arthur Hurst described a condition defined as 
‘‘postdysenteric colonic irritability’’ (21). This condition was quite frequent in British 
troops returning from war campaigns in areas endemic for bacillary or amoebic 
gastroenteritis. Over the past decade, this concept has been revitalized and PI-IBS has 
been reported to develop in 3% to 30% of individuals after bacterial gastroenteritis 
(22). A recent systematic review and meta-analysis identified that the pooled incidence 
for IBS development after infectious gastroenteritis was 10% (23). Salmonella, 
Shigella, and Campylobacter are among the most frequently isolated infectious agents 
(16), but viral infection has also been documented as a trigger of IBS  (24, 25). Connell 
(26) postulated that in the United States organisms such as Shigella or Salmonella are 
being replaced in frequency by Campylobacter, Chlamydia and Giardia.  
 
The underlying mechanism of post-infectious IBS has not been established but ongoing 
inflammation appears to play a role, with an increase in enteroendocrine cells, 
lymphocytes, mast cells, and proinflammatory cytokines (27). Intestinal dysbiosis 
induced by infection also has been proposed to produce low-grade inflammation and 
chronic gut dysfunction (16).  
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1.5.2 IBS and inflammation 
An immune activation and inflammatory response at the mucosal level may play a role 
in generating and perpetuating symptoms in patients with IBS. It is well known that 
patients with inflammatory bowel disease frequently develop symptoms overlapping 
those of IBS patients (28, 29). Several studies revealed the presence of intestinal 
inflammation in IBS (30). Both innate and adaptive immune responses seem to be 
involved in IBS pathogenesis (31). Histopathologic data demonstrated low-grade 
inflammation in intestinal mucosa and ganglia in a subset of patients with IBS (17). 
Increased numbers of immunocytes, mainly lamina propria T cells, intraepithelial 
lymphocytes (IELs), and mucosal mast cells, have been observed in intestinal mucosa 
biopsies from IBS patients when compared with specimens from asymptomatic control 
subjects (32, 33). 
 
Some studies have shown that patients with IBS have increased plasma levels of 
interleukins 6 and 8 (IL6 and IL8) (34, 35), which are proinflammatory cytokines 
primarily produced by monocytes and macrophages. Spiller et al. (36) found 50% 
reduction in the number of resident mucosal macrophages in rectum but increased 
levels of activated macrophages identified by calprotectin expression in patients with 
PI-IBS. Mast cells and resident macrophages are key players in the early immune 
response to microorganisms that affect the mucosal tissue. The secretion of immune 
mediators by these cell populations is crucial for recruitment of phagocytic cells, 
macrophages and neutrophils to the damaged tissue (31).  
 
1.6 ENTEROENDOCRINE CELLS 
The gastrointestinal tract contains the largest endocrine organ in the body. 
Enteroendocrine cells (EEC) are present in the mucosa of the stomach, small intestine, 
colon, and rectum and are highly specialized cells that produce hormones and other 
signalling substances that are vital to the normal function of the gut. Due to their 
diffuse localisation EEC are difficult to study and so far, their role in the pathogenesis 
of bowel disorders has been only little explored. A well characterised subset of EEC are 
the enterochromaffin cells, which are the main source of the biogenic amine serotonin 
(5-hydroxytryptamine, 5-HT) in the GI tract (37). The aminoacid tryptophan serves as a 
precursor for the production of serotonin, which is transported from the cytosol to large 
dense-core secretory vesicles (LDCV) by the vesicular monoamine transporter 
(VMAT1), a glycoprotein located in the membrane of LDCV (38). 
 
Serotonin influences the intestinal homeostasis by altering gut physiology (motility and 
secretory function) and has been implicated in the pathophysiology of various GI 
disorders, including inflammatory bowel disease (IBD) and IBS (39). The mechanisms 
regulating serotonin homeostasis in EEC during infection and inflammation processes 
are yet unclear. Chromogranin A (CgA) is a well known protein constituent of LDCVs 
and has been identified as a “common denominator” peptide for EEC (40). CgA is 
released by regulated secretion in response to extracellular stimulation of the cells (41) 
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and can furthermore act as an on/off switch for secretory granule biogenesis (42). 
Elevated serum levels of CgA have been reported in both IBD (43) and IBS (44). 
 
EEC play a pivotal role in sensory signalling for the enteric reflex regulating intestinal 
propulsive motility and secretion under basal and stress-sensitive manifestations of 
functional bowel disorders (45). Alteration of endocrine cell function, particularly in 
the context of serotonin (5-HT), has been shown to be associated with a number of GI 
diseases including inflammatory bowel disease (IBD), coeliac disease, and IBS (46-48). 
The association between alteration in the production of gut hormones from enteric 
endocrine cells and various GI diseases emphasizes the significance of these cells in 
intestinal homeostasis (45).  
 
In addition, EEC seems to be an important contributor to inflammatory processes 
occurring in the gut in response to pathogens (49) and an increased number of serotonin 
positive EEC has been observed in post-infectious IBS (36). Alterations in the number 
of EEC have been observed in different bacterial, viral and parasitic infections of the 
GI tract (50). EEC can be activated by bacterial ligands like lipopolysaccharide (LPS) 
and may play a role in immune activation and in the regulation of gut inflammation 
(51). Altered endocrine function of the gut accompanies the inflammatory immune 
response (52).  
 
1.7 IBS AND MICROBIOTA 
Abnormalities in the gut flora may be of importance in the pathogenesis of IBS as the 
gut flora can modulate the immune response. The human microbiota consist of about 
100 trillion microbial cells that outnumber our cells by 10 to 1 (53). The human 
gastrointestinal microbiota have been extensively studied but is not yet fully described. 
In the healthy host, enteric bacteria colonize the alimentary tract soon after birth, and 
the composition of the intestinal microflora is believed to remain relatively constant 
throughout life (54). Maternally acquired bacteria during birth are followed by 
hundreds of environmentally acquired species, which differ between individuals but 
mainly belong to two bacterial phylotypes, Firmicutes spp. and Bacteroidetes spp. (55). 
In a recently published metagenomic study Arumugam et al. (56) identified three major 
enterotypes in the humen gut microbiome; these were dominated by Bacteroides, 
Prevotella, and Ruminococcus, respectively. 
 
The adult human intestine is home to between 1000 and 1150 prevalent bacterial 
species (57), which normally remain confined to the distal gut (colon) where the 
concentration of organisms is approximately 1011 organisms per gram of content (58). 
Because of peristalsis and the antimicrobial effects of gastric acidity, the stomach and 
proximal small intestine contain small numbers of bacteria in healthy individuals. The 
bacterial counts of coliforms rarely exceed 103 colony-forming units (CFU)/mL in 
jejunal juice (54). The intestinal epithelium provides an essential barrier between host 
and microbe. However, there is constant cross-talk across this barrier between the 
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immune system and microbiota that is equally important for homeostasis in the gut 
(59). 
 
The relationships between microbiota and different diseases in the gut have been 
studied regarding colonic microbiota and some associations have been observed for 
inflammatory bowel diseases (IBD) (57, 60), metabolic syndrome (61), and obesity 
(62). A contribution of the gastrointestinal microbiota has been suggested in IBS (63). 
Intestinal dysbiosis induced by infection also has been proposed to produce low-grade 
inflammation and chronic gut dysfunction in IBS (16). 
  
The potential differences of the intestinal microbiota between IBS patients and healthy 
controls (HC) have mostly been studied using fecal material, as this is the most 
accessible source of the GI microbiota (63, 64), but fecal samples reflect mostly colonic 
flora. Small bowel microflora is not fully described, partly because small bowel 
samples are relatively difficult to access. Kerckhoffs et al. (65) found decreased 
Bifidobacteria levels in both fecal and duodenal brush samples of IBS patients 
compared to healthy subjects. Small intestinal bacterial overgrowth (SIBO) has been 
proposed to be common in IBS (66). Bacterial overgrowth is a condition caused by an 
abnormal number of bacteria in the small intestine, exceeding 105 organisms/ml (5 log 
colony-forming unit (CFU)/ml) owing to different predisposing conditions, such as 
impaired motility or failure of the gastric-acid barrier (67, 68). The direct aspiration and 
culture of jejunal fluid, with results expressed as CFU/mL of jejunal fluid, although 
invasive, has been regarded by many investigators as the gold standard for the 
diagnosis SIBO but molecular techniques such as genomics and metabolomics suggest 
that as much as 60% of the normal flora is not identified by culture-based methods (54).  
 
1.8 IBS AND CHLAMYDIA 
Connell (26) postulated that in the United States infections with organisms such as 
Shigella or Salmonella prior to PI-IBS are being replaced in frequency by 
Campylobacter, Chlamydia and Giardia. Törnblom et al. (25) showed that the actual 
agent causing gastroenteritis was not a predictor of risk for IBS. Consequently, a host 
factor, such as a pre-existing chronic infection with a different microbe than the agent 
causing gastroenteritis, might explain the development of IBS. Such a candidate agent 
should be compatible with an asymptomatic carrier-ship, have a preference for female 
gender, and have the ability to become persistent and to live in bowel epithelium. There 
are some observations to support the idea that a persistent infection with Chlamydia 
trachomatis might constitute such a host factor.  
 
Bacteria of the genus Chlamydia are gram-negative, obligate intracellular pathogens, 
which multiply and infect a wide range of eukaryotic cells causing both chronic and 
acute diseases in humans and animals (69). The growth of Chlamydia is characterised 
by a unique developmental cycle with morphologically distinct infectious (elementary 
body (EB)) and reproductive forms (reticulate body (RB)). Upon infection, the EB 
differentiates into the metabolically active RB, which is able to replicate within the host 
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inside a membrane-bound compartment, termed inclusion. In association with chronic 
diseases, alterations of the life cycle such as a persistent state leading to asymptomatic 
infections have been discussed for C. trachomatis (69). Bacteria in a persistent state 
down-regulate their metabolism and may exhibit atypical morphology. They may 
therefore be difficult to detect for the immune system and they are relatively 
inaccessible for antibiotic therapy (70). Trachoma-related blindness is 2-4 times more 
likely to affect females compared to males (71). It is known that IBS occurs in 35%-
50% of females with chronic pelvic pain syndrome, which is believed to often be 
caused by chronic infection with C. trachomatis (4, 72, 73). A previous attempt to link 
C. trachomatis to IBS using serum IgG antibodies failed (74), but IgG antibody 
patterns may be insufficient to rule out persistence of Chlamydia due a dominating 
cellular immune response to infection (75, 76). 
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2 AIM OF STUDY 
The general aim of this thesis was to assess the role of bacteria in the pathogenesis of 
IBS.  
 
The following research questions were central to the studies included in this thesis: 
 
• The aim of study I was to find out if Chlamydia antigens were present in the 
small bowel in patients with severe IBS. 
• The aim of study II was to characterise the interaction between Chlamydia and 
EEC in vitro using enteroendocrine cell lines from both small bowel and large 
bowel. 
• The aim of study III was to evaluate the response pattern of enteroendocrine 
cells to intracellular bacteria in vitro using microarray technology.  
• The primary aim of study IV was to deeply explore the composition of small 
bowel mucosa-associated microbiota using pyrotag sequencing. The secondary 
aim of study IV was to study differences in small bowel mucosa associated 
microbiota between IBS patients and healthy controls. 
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3 MATERIAL AND METHODS 
The patients and controls included in study I and IV received oral and written 
information before consenting to participation in the studies. In study I we reanalyzed 
archived biopsy material. The local Ethics Committee at Karolinska University 
Hospital, Huddinge, Stockholm, Sweden (HS 144/98, HS 517/98, HS 518/98, HS 
39/02) and the Regional Board of Research Ethics, Stockholm (2006/398-31/2, 
2006/1328-31/1, 2007/1151-31/2) approved all human studies. 
 
3.1 SUBJECTS 
3.1.1 Study I 
All patients fulfilled Rome-II criteria for IBS. A total of 65 patients (61 females and 4 
males) with a median age of 48 (range 22-67) years and a median duration of IBS 
symptoms of 6.5 years (range 0.6-33.2 years) were investigated. Diarrhoea 
predominant IBS was present in 21 patients (32%), 22 patients (34%) had constipation 
predominant IBS and 22 patients (34%) had IBS with alternating bowel habits. All 
patients had severe symptoms of IBS and 26 patients also exhibited abnormalities on 
small bowel manometry, thus qualifying for a pathophysiological diagnosis of enteric 
dysmotility. Full thickness jejunum biopsies had been taken in 60 of our patients. 
Previous histopathological analysis had revealed neuropathic changes in 58 patients. 
Neuropathy was associated with low-grade inflammation (LG = lymphocytic 
ganglionitis) in 46 patients and 20 of these also exhibited increased numbers of 
intraepithelial lymphocytes (LEG = lymphocytic epithelio-ganglionitis), whereas 12 
patients had degenerative neuropathy (DN) without inflammation. Deficient staining 
for alpha-actin without neuronal damage was observed in 2 patients. 
 
The control group comprised 42 persons (29 females) in whom IBS and all other 
functional bowel disorders had been excluded by medical interview and a validated 
questionnaire for the Rome-II symptom criteria. Ten controls (7 females) were obese 
but otherwise healthy (BMI mean = 42.8, SD = 4.3). The rest of the control group (32 
persons, 22 females) consisted of healthy volunteers with normal weights. The median 
age of the controls was 36 (range 19-60) years. 
 
3.1.2 Studies II and III 
Studies II and III were in vitro studies on human enteroendocrine cell lines. 
 
3.1.2.1 Cell lines 
We used two different human enteroendocrine cell lines: LCC-18, derived from a 
neuroendocrine colonic tumour and CNDT-2, derived from a small intestinal carcinoid. 
LCC-18 cells (a kind gift from K. Öberg, Uppsala University Hospital, Uppsala, 
Sweden) were maintained in DMEM/F-12 medium (Invitrogen, UK) supplemented 
with 5% fetal bovine serum (FBS) transferrin, β-estradiol, insulin, hydrocortisone, 
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sodium selenite (Sigma-Aldrich, Sweden) and HEPES buffer (Invitrogen). CNDT-2 
cells (a kind gift from LM. Ellis, University of Texas, Houston, USA) were cultured in 
DMEM/F12 medium (Invitrogen), supplemented with 10 % FBS, vitamin solution, L-
glutamine and HEPES (Invitrogen). Both cell lines were incubated at 37 °C in a 5 % 
CO2 humidified environment. 
 
3.1.2.2 Chlamydial strains and infection 
Chlamydia trachomatis L2 strain 434 (ATCC) was propagated in HeLa cells as 
described by Boleti et al. (77) For infection experiments, LCC-18 and CNDT-2 cells 
were inoculated with Chlamydia at a multiplicity of infection (MOI) of 0.5-1 for 1 h at 
37°C. Monolayers of infected CNDT-2 cells were washed with PBS (phosphate 
buffered saline) and incubated in fresh media. Infected LCC-18 cells were spun at 500 
x g for 5 min to pellet the cells. The inoculum was removed and fresh media containing 
8 µg/ml gentamycin (Invitrogen) to kill off extracellular bacteria was added for the 
indicated times. To induce persistent infection, LCC-18 and CNDT-2 cells were 
infected and incubated in medium containing 100 U/ml penicillin G (Sigma-Aldrich) 
for 24 h at 37°C. 
 
3.1.3 Study IV 
All patients fulfilled Rome-II criteria for IBS. A total of 35 patients (26 females) with a 
median age of 36 (range 18-50) were investigated. Diarrhoea predominant IBS (D-IBS) 
was present in 13 patients (37%), 9 patients (26%) had constipation predominant IBS 
(C-IBS) and 13 patients (37%) had IBS but did not fulfil criteria for D-IBS or C-IBS 
(M-IBS). 
 
The control group comprised 16 healthy volunteers (11 females) in whom IBS and all 
other functional bowel disorders had been excluded by medical interview and a 
validated questionnaire for the Rome-II symptom criteria. The median age of the 
controls was 32 (range 20-48) years. Obesity was excluded in both patients and 
controls. 
 
3.2 METHODS 
3.2.1 Full thickness jejunum biopsy (I) 
Previously obtained full-thickness biopsy specimens were available in 60/65 patients. 
The biopsies had been taken from the proximal jejunum using a laparoscopy assisted 
procedure described by Törnblom et al. (17). Ten obese controls underwent full 
thickness biopsy of the jejunum at the time of gastric by-pass surgery. 
 
3.2.2 Mucosa biopsy (I, IV) 
Mucosa specimens from the proximal jejunum were taken with a Watson capsule in 32 
controls and 41 patients (6 patients in study I and 35 patients in study IV). The capsule 
was swallowed by the subject and brought by peristalsis to a position distal to the 
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ligament of Treitz as determined by fluoroscopy. In study I we analyzed also archived 
endoscopic mucosa biopsies from the duodenum of 20 patients and in 15 of these full 
thickness biopsies were also available. In 2 patients we analyzed mucosa biopsies from 
both the jejunum and the duodenum. The presence of villous atrophy or inflammation 
was excluded in all biopsies. 
 
3.2.3 Immunofluorescence (I, II) 
The following antibodies were used for immunofluorescence and immunohisto-
chemistry: 
 
Target Primary antibody Secondary antibody 
Chlamydia 
lipopolysaccharide (LPS) 
Mouse monoclonal - 
FITC conjugated with 
Evans blue 
- 
C. trachomatis major outer 
membrane protein (MOMP) 
Mouse monoclonal Rabbit polyclonal anti-
mouse -FITC conjugated 
C. pneumoniae MOMP Mouse monoclonal Rabbit polyclonal anti-
mouse - FITC conjugated 
C. trachomatis LPS Rabbit polyclonal Goat anti-rabbit  
Streptavidin-biotin complex 
Chromogranin A Rabbit polyclonal Goat anti-rabbit conjugated 
with Alexa Fluor 568  
Serotonin Rabbit polyclonal Goat anti-rabbit conjugated 
with Alexa Fluor 568  
Mast cells CD117 Rabbit polyclonal Goat anti-rabbit conjugated 
with Alexa Fluor 568  
Macrophages CD68 Rabbit polyclonal Goat anti-rabbit conjugated 
with Alexa Fluor 350 
Dendritic cells CD11c Rabbit polyclonal Goat anti-rabbit conjugated 
with Alexa Fluor 350 
 
Stained sections were examined using a Universal Laser Scanning Confocal 
Microscope System Leica TCS and a Fluorescent Microscope System Leica DMRXA 
(Leica Microsystems, Wetzlar, Germany).  
 
In study I two independent investigators (AD and GM), who were unaware of clinical 
data, made the final assessment of slides. The slides were reviewed by a third 
investigator (BV). The immunofluorescence stainings were considered positive if more 
than one cell showed fluorescence. If only one positive cell was found, the staining-
procedure was repeated. The case was regarded positive if the colour signal was again 
present, otherwise the case was recorded as negative. Double immunofluorescence 
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stainings were also performed for the identification of LPS positive cells (LPS with 
chromogranin, CD68, CD117, or CD11c, respectively). 
 
3.2.4 Western blotting 
Snap-frozen biopsies from 4 patients that were positive for Chlamydia LPS staining, 
were examined by Western blotting. HeLa cells infected with C. trachomatis served as 
positive control and we used non-infected HeLa cells as negative control. Equivalent 
amounts of protein from each specimen were loaded onto a sodium dodecyl sulphate- 
polyacrylamide gel. After electrophoresis, samples were transferred to nitrocellulose 
membranes. We used a mouse monoclonal antibody to C. trachomatis LPS (AbD 
Serotec, Oxford, UK) as primary antibody and goat anti-mouse antibody conjugated to 
horseradish peroxidase (BioRad, Herculaes, CA, USA) as secondary antibody. For 
MOMP we used the same primary antibody as for immunofluorescence. 
 
3.2.5 Microlaser system (I) 
We used Laser Microdissection Pressure Catapulting (LMPC) for laser based non-
contact extraction of tissue areas in paraffin embedded biopsies from 6 patients. 
Regions of interest were manually delineated using fluorescence microscopy and the 
LMPC software. Tissue collection was achieved by laser cutting along the delineation 
lines to separate tissue of interest from surrounding regions, and secondly the laser 
catapulted the tissue of interest up into the lid of an Eppendorf cap containing sterile 
water. DNA was extracted using the QIAamp DNA mini kit, according to the 
instructions of the manufacturer, and analyzed by PCR. 
 
3.2.6 Transmission electron microscopy (I, II, III) 
In study I biopsies from the distal duodenum of 4 patients that were positive for 
Chlamydia LPS staining were fixed according to a procedure described by Muschiol et 
al. (78). Semi thin sections were cut and stained with toluidin blue and used for light 
microscopic analysis. Ultra-thin sections were contrasted with uranyl acetate followed 
by lead citrate and examined in a Tecnai 10 transmission electron microscope at 80 kV. 
Digital images were taken by using a MegaView III digital camera (Soft Imaging 
System, Münster, Germany). 
 
In studies II and III cells were grown in 6-well plates and infected with Chlamydia 
trachomatis L2 in presence or absence of penicillin G as described. At 24 h post 
infection the cells were harvested, fixed in 0.1 M sodium cacodylate buffer (pH 7.4) 
containing 2 % glutaraldehyde, 0.5 % paraformaldehyde, 0.1 M sucrose and 3 mM 
CaCl2 and prepared for transmission electron microscopy as previously described  and 
analysed in a BioTWIN (Fei, The Netherlands). Digital images were obtained by a 
Veleta digital camera (Soft Imaging System, Germany). 
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3.2.7 Real-time PCR (I, II) 
In study I we used the real-time PCR assay developed by Everett et al. (79), which 
amplifies 23S ribosomal DNA and detects all members of the family Chlamydiaceae. 
An internal amplification control was included to monitor possible inhibition of the 
PCR. DNA from frozen biopsies, taken from 4 patients previously positive for 
Chlamydia LPS staining, was extracted using a Qiagen minikit according to the tissue 
protocol (Qiagen, Solna, Sweden). Extracted DNA was quantified and quality 
controlled using a Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, 
DE, USA) before being subjected to PCR. 
 
In study II total RNA from non-infected, infected and persistently infected cells was 
extracted using the RNeasyMini RNA extraction kit (Qiagen, Germany) including an 
on-column DNase treatment procedure, following the manufacturer’s instructions. PCR 
amplification of selected target genes: chromogranin A (CHGA), vesicular monoamine 
transporter (VMAT1), glutamate receptor metabotropic 4 (mGluR4), tryptophan 
hydroxylase 1 (TPH1), transient receptor potential cation channel (TRPA1), 
transcription factor CP2 (TFCP2), heat shock protein 1 (HSPB1) and toll-like receptor 
4 (TLR4) was performed under the following conditions: 1 cycle at 50 °C for 2 min; 1 
cycle at 95 °C for 10 min, 45 cycles at 95 °C for 15 s; and 60 °C for 60 s, with 
fluorescence acquisition at 60 °C. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) served as internal normalization control and relative expression values were 
assessed from triplicates per real-time PCR assay and five technical replicates relative 
to a calibrator value (non-infected cells).  
 
The following primers were used:  
 
Target gene Sense Antisense 
CHGA GCATCGTTGAGGTCATCT ACCGCTGTGTTTCTTCTG 
VMAT1 ACACATACACAGAATCCTCAG TCAACTTGCCAGCTTATCC 
mGluR4 CCAGGCTACCACAAGAAC CCAACAGCACAGACAGAG 
TPH1 ATATACCATACAAGCCACTGAC CATAATACTCCTCAAGTTATTCTAAGC 
TRPA1 TGACGATATGGACACCTT AAGACCTTCATCACCTCAT 
TFCP2 TGGATTTGGTTCTAAGCCGTG CCCAGGTCTCGCTCTCTC 
HSPB1 CTCAAACACCGCCTGCTA GCTGACTCTGCTCTGGAC 
TLR4 TTCAAGGTCTGGCTGGTT CGAGGTAGTAGTCTAAGTATGCTA 
GAPDH GGTCGGAGTCAACGGATT ATCGCCCCACTTGATTTTG 
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3.2.8 Microarray (III) 
In study III total RNA was isolated from 1 x 106 LCC-18 and CNDT-2 cells infected 
with Chlamydia trachomatis L2 (MOI 1) in presence or absence of penicillin G for 24 
h. RNA samples were prepared using the RNeasy Mini kit (Qiagen) including an on-
column DNase treatment step according to the manufacturer´s instructions. RNA 
concentrations were measured with a ND-1000 spectrophotometer (NanoDrop 
Technologies, USA) and RNA quality was assesed using the Agilent 2100 Bioanalyzer 
system (Agilent Technologies Inc, USA). 250 nanograms of total RNA from each 
sample were used to generate amplified and biotinylated sense-strand cDNA according 
to the Ambion WT Expression Kit (P/N 4425209 Rev B 05/2009) and Affymetrix 
GeneChip® WT Terminal Labeling and Hybridization User Manual (P/N 702808 Rev. 
1, Affymetrix Inc., USA). GeneChip® ST Arrays (GeneChip® Mouse Gene 1.0 ST 
Array) were hybridized for 16 hours in a 45 °C incubator, rotated at 60 rpm. According 
to the GeneChip® Expression Wash, Stain and Scan Manual (PN 702731 Rev 2, 
Affymetrix Inc., USA) the arrays were then washed and stained using the Fluidics 
Station 450 and finally scanned using the GeneChip® Scanner 3000 7G. 
 
3.2.9 DNA extraction (IV) 
Extraction of total genomic DNA (gDNA) from frozen biopsies was performed with 
the DNeasy Blood & Tissue Kit (Qiagen, Germany). Biopsy samples where 
homogenized with a pestle in 1.5 ml tubes containing 200 µl freezing buffer. 100 µl of 
the homogenate was added to 200 µl lyses buffer (180 µl ATL buffer, 20 µl Proteinase 
K) and incubated overnight at 56°C in a shaking incubator. A negative extraction 
control was included for each batch of DNA extraction. After extraction of gDNA 
following the manufacturer’s instruction the gDNA was eluted in 100 µl Buffer AE and 
stored at -20°C until further usage. 
 
3.2.10 PCR and template preparates for 454-sequencing (IV) 
The protocol for barcoded 454-pyrosequencing has been adapted from Andersson et al. 
(80). In order to create barcoded sequencing templates, PCR was performed using 
barcoded reverse primer 805r (1-55) targeting the 16S rRNA gene. For each sample, a 
PCR mix was prepared (triplicate) containing 1x PCR buffer, 10mM dNTP´s 
(Finnzymes, Finland), 1 U Phusion High-Fidelity DNA Polymerase (Finnzymes, 
Finland), 0.4 µM of each primer and 1-5 µl template DNA. For the PCR reaction the 
following conditions were applied: after an initial denaturation step ( 95°C, 5 min), 30 
cycles of 95°C for 40 sec, 55°C for 40 sec and 72°C for 60 sec were followed by an 
final elongation step with 72°C for 10 min. Following agarose gel electrophoresis (1% 
agarose in TBE buffer containing gel red (Sigma Aldrich, Sweden), PCR products with 
the right size (approx. 500 bp) were excised and purified using the QIAquick gel 
extraction kit (Qiagen, Germany). The DNA concentration was assessed using the 
Qubit Fluorometer (Invitrogen, USA). After an initial concentration determination, the 
PCR products were diluted to a concentration between 3 and 5 ng/µl and then pooled 
for the 454 sequencing run. The final concentration of the DNA pool was measured for 
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further dilutions for the emulsion PCR (emPCR) in the 454 workflow. Pyrosequencing 
was performed according to the Genome Sequencer FLX System Methods Manual. 
 
3.2.11 Data analysis (IV) 
3.2.11.1 Sequence processing 
The raw sequences from the 454 pyrosequencing run were processed to eventually 
assign the sequences a taxon. All sequences that i) contained ambiguous nucleotides ii) 
were shorter than 200 bases (primer sequence and barcode tag excluded) or iii) did not 
perfectly match the barcode or primer, were removed. The remaining sequences were 
trimmed down to 200 bases excluding barcode and primer. The RDP Pyrosequencing 
Pipeline (http://rdp.cme.msu.edu/) was then used for alignment and clustering of the 
non-redundant sequences into Operational Taxonomic Units (OTU), using complete 
linkage clustering and a 3% distance threshold. The most prevalent sequence within 
each OTU was used for taxonomic classification of the OTU. 
 
3.2.11.2 Taxonomic classification 
A local BLAST database was created from 16S rRNA gene sequences longer than 1200 
bases and with good pintail score, downloaded from the Ribosomal Database Project 
(RDP) website (release 10, update 15). All OTU representative sequences were BLAST 
searched against the local database using default parameters. The OTUs were assigned 
the taxonomic classification of the best scoring RDP hit if the identity similarity to this 
was at least 95% over at least 180 nucleotides. The OTU was classified as a 
“no_match” if no such hit was found. If there were several equally good (with the same 
score) BLAST hits for an OTU, the taxonomy was taken down to the level, which was 
consistent for all the hits. The normalized values for the number of sequences assigned 
to each taxon (relative abundance of each taxon) were used for comparison of samples. 
MultiExperiment Viewer 4_0 (TMEV) (http://www.tm4.org/mev/) was used to 
visualize the relative abundance of the different OTUs in a heatmap. 
 
3.2.11.3 Sample clustering 
The online version of Fast Unifrac (http://bmf2.colorado.edu/fastunifrac/) was used for 
calculating weighted sample distances using the Greengenes reference sequences and 
the corresponding tree (downloaded from the Fast Unifrac website). We first clustered 
our sequences into OTUs using 1% distance threshold and the most prevalent sequence 
for each OTU was mapped to the best matching Greengenes sequence by using BLAST 
and an e-value cutoff of 10-30 (81). Based on pair-wise sample differences (Unifrac 
values), a Principal Coordinates Analysis (PCoA) plot was created on the Fast Unifrac 
website. 
 
3.3 STATISTICAL METHODS 
In Study I we used logistic regression with age and gender as covariates for calculation 
of odds ratios and p-values for comparisons of proportions. The size of the study group 
was determined from the assumption that LPS positivity would be no greater than 20% 
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among controls. In order to detect a risk factor with an odds ratio of at least 6 at p<0.01 
with power >90% we needed to include at least 37 patients and 37 controls (two-sided 
test). 
 
Differences in gene expression between infected and non-infected cells in Study II were 
analysed using Student’s t-test. Differences in staining intensity were analysed using 
analysis of variance (ANOVA). A p-value of less than 0.05 was considered statistically 
significant. 
 
In Study III subsequent analysis of the gene expression data was carried out in the 
freely available statistical computing language R (http://www.r-project.org) using 
packages available from the Bioconductor project (http://www.bioconductor.org). The 
raw data was normalized using the robust multi-array average (RMA) method first 
suggested by Li and Wong in 2001 (82, 83). In order to search for the differentially 
expressed genes between acute and persistent infection and the control samples (non-
infected) an empirical Bayes moderated t-test was applied (84), using the ‘limma’ 
package (85). 
 
To address the problem with multiple testing, p-values were adjusted using the method 
of Benjamini and Hochberg (86). Genes with an expression ratio ≥2-fold and adjusted 
p<0.05 were regarded as differentially transcribed genes (87). Gene clustering was 
performed using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) (http://david.abcc.ncifcrf.gov). 
 
In Study IV significant differences at phylum, class, genus and OTU level were 
investigated using the Bioconductor R package (88), comparing all groups to each other 
(M-IBS with controls, C-IBS with controls, D-IBS with controls). EdgeR returns a non-
paired p-value for each taxon taking the actual number of reads of the different samples 
into account. The probability for false positive significant differences was also 
calculated to correct for multiple testing (False Discovery Rate). Shannon diversity 
index, a measure of biodiversity, was calculated for each of the four groups (controls, 
D-IBS, C-IBS and M-IBS) and also for all IBS cases as one group (89). The Shannon 
diversity index takes into account the number of species present and also the evenness 
of these species (90). 
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4 RESULTS 
4.1 THE PRESENCE OF CHLAMYDIA IN THE SMALL BOWEL OF 
PATIENTS WITH SEVERE IBS (I) 
4.1.1 Immunofluorescence and Western blot 
65 patients (61 females) with severe IBS and 42 (29 females) healthy controls without 
IBS were included. Immunofluorescence (IF) staining showed that 53/60 patients were 
positive for Chlamydia LPS in full thickness jejunum biopsies and 21/24 (88%) 
patients in mucosa biopsies. Positive staining occurred in a few cells both within the 
epithelium and in lamina propria. No Chlamydia LPS-positive cells were found in the 
submucosa and muscularis propria or the enteric nervous system in full thickness 
jejunum biopsies. In 19 patients biopsies had been taken with a time interval of more 
than 1 year. Chlamydia LPS was present in biopsies with a median time difference of 
5.2 (range 1-11) years. Overall, 58/65 (89%) patients were classified as Chlamydia LPS 
positive. Six women and one man with IBS were negative in all biopsies. In 90% of 
positive biopsies from patients Chlamydia LPS was localised to mucosal cells at the 
level of the crypts. Double staining with antibodies to chromogranin- A showed that 
Chlamydia LPS was present in enteroendocrine cells within the epithelium. Chlamydia 
LPS was found in l. propria cells in 69% of the biopsies from patients. Double staining 
with antibodies to CD117, CD11c and CD68 revealed that in this location Chlamydia 
LPS was present in macrophages. Seventy-nine percent of Chlamydia LPS positive 
biopsies were also positive to C. trachomatis MOMP. Staining for C. pneumoniae was 
negative in all patients. We confirmed the presence of Chlamydia LPS antigen in new 
biopsies taken from duodenum mucosa in 4 LPS-positive patients with Western 
blotting but the new biopsies were negative for C. trachomatis MOMP both in 
immunofluorescense and Western blot. 
 
Only 6/42 (14%) controls (5 women) were positive for Chlamydia LPS (6 in l. propria 
macrophages and 2 in enteroendocrine cells) and 2/6 LPS-positive controls were 
positive to C. trachomatis MOMP. No biopsies from controls were positive for C. 
pneumoniae. The prevalence of Chlamydia LPS was much higher in patients with IBS 
(58/65) than it was among controls (6/42). The odds ratio, corrected for differences in 
age and gender distributions, for mucosal Chlamydia LPS being indicative for presence 
of IBS was 43.1 (95% CI: 13.2- 140.7). Biopsies were analysed by two independent 
investigators unaware of clinical data. The agreement between the two investigators 
regarding individual biopsies was 94%, whereas their agreement regarding patient 
classification was 100%. We found no correlation between presence of Chlamydia 
antigens and the type of neuropathy in patients with full thickness biopsies. Although 
the majority of patients had neuropathy with inflammation, Chlamydia antigens were 
common also among those who had neuropathic changes without inflammation (LEG: 
19/20 = 95%; LG 23/26 = 88%; DN 9/12 = 75%). We found no difference between IBS 
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subgroups with regard to positivity for Chlamydia antigens and 19/21 with D-IBS, 
22/22 with C-IBS, and 17/22 with A-IBS were LPS positive. 
 
4.1.2 Transmission electron microscopy 
Electron microscopy of biopsies taken from the duodenum mucosa in 4 LPS-positive 
patients revealed small oval structures resembling intermediate bodies of Chlamydia 
with characteristic condensed nucleoids of nucleic acid. Mitochondria were observed 
surrounding the inclusions but did not appear to be in close association with the 
inclusions. 
 
4.1.3 Real-time PCR 
We were unable to confirm the presence of Chlamydia DNA in new biopsies taken 
from the  duodenum mucosa in 4 LPS positive patients using 23S ribosomal DNA as 
target. Results were negative for Chlamydia DNA also when we analyzed micro-
dissected Chlamydia LPS positive cells. 
 
4.2 INTERACTION BETWEEN CHLAMYDIA AND HUMAN 
ENTEROENDOCRINE CELLS IN VITRO (II) 
4.2.1 Immunofluorescence 
 
A 
 
B 
Figure 1. Altered cellular distribution of chromogranin A in EEC after infection with 
Chlamydia trachomatis L2. A: Cytoplasmatic distribution of chromogranin A (CgA) in 
non-infected LCC-18 cells (rabbit CgA antibody and Alexa 568-red and DAPI nucleus 
staining (blue), original magnification x63). B: Chromogranin A labelling in Chlamydia 
containing inclusions in infected LCC-18 cells (rabbit CgA antibody and Alexa 568-red 
and DAPI nucleus staining (blue), original magnification x63). 
 
Immunofluorescence demonstrated differences in the cellular distributions of serotonin 
and CgA between infected and non-infected cells. In infected cells serotonin and CgA 
were mainly localized within chlamydial inclusions (Figure 1 B), whereas in non-
infected cells these markers predominantly exhibited a cytoplasmatic distribution 
(Figure 1 A). Mean staining intensity was measured using Nikon NIS Elements. 
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Differences in staining intensity between inclusions and cytoplasm of both infected and 
non-infected cells, and between cytoplasm of infected and non-infected cells were 
highly significant (p<0.0001) for both serotonin and CgA staining in both cell lines. No 
serotonin or CgA was detected in infected or non-infected HeLa cells, which in this 
instance served as negative control. 
 
4.2.2 Transmission electron microscopy 
In order to investigate whether C. trachomatis is able to grow and multiply within EEC, 
human EEC from both the colon (LCC-18) and the small bowel (CNDT-2) were 
infected with C. trachomatis and incubated for 24 h. TEM confirmed the growth of C. 
trachomatis, manifested through inclusions containing both elementary bodies (EB) 
and reticulate bodies (RB), for both cell lines (Figure 2 A). Similar growth was 
observed in HeLa cells, which were used as positive control (data not shown). Similar 
to previously described infection cycles in other cell types, C. trachomatis successfully 
infected and multiplied within the confinements of the inclusion in EEC and yielded 
productive EBs and this can therefore be considered as an active infection (data not 
shown). To investigate whether the persistent life-cycle could be induced in the EEC, 
cells were infected with C. trachomatis and incubated in the absence and presence of 
penicillin G (penG), which has been demonstrated previously to induce persistent 
growth of Chlamydia in HeLa cells (91). When EEC were treated with penG we 
observed enlarged, aberrant bacteria reminiscent of persistent growth forms suggesting 
that persistence can be induced in both EEC tested (Figure 2 B). 
 
 
A 
 
B 
Figure 2. Infection of enteroendocrine cells from cell line LCC-18 with Chlamydia 
trachomatis. A: Active infection. B: Persistent infection. 
 
4.2.3 Real-time PCR 
In order to analyze the infection of EEC with C.trachomatis at the molecular level, we 
investigated the expression of selected target genes using real time PCR. Genes coding 
for EEC protein markers (CHGA, VMAT1, mGluR4, TPH1, TRPA1), house-keeping 
proteins (TFCP2, GAPDH), enviromental stress marker (HSPB1) as well as TLR4, 
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which is believed to mediate the main line of response upon Chlamydia infection, 
where subjected to PCR analysis. Transcriptomes of C. trachomatis infected EEC 
(LCC-18 and CNDT-2) were analysed after 24h. The same time-point was investigated 
after induction of persistence using penicillin G. We found significant down-regulation 
of VMAT1 expression in persistent infection compared to non-infected cells (p<0.05) 
and up-regulation of TLR4 expression in active and persistent infection (p<0.05). 
Expression of CHGA, the gene coding for CgA, as well as TPH1 and TRPA1, genes 
coding for proteins associated with serotonin synthesis and release, were not changed 
upon infection with Chlamydia. Gene expression changes were associated with 
infection and did not appear in cells exposed to heat-treated bacteria. 
 
4.3 RESPONSE PATTERNS OF ENTEROENDOCRINE CELLS TO 
INTRACELLULAR BACTERIA IN VITRO (III) 
4.3.1 Transmission electron microscopy 
With TEM we confirmed C. trachomatis active and persistent infection in 
enteroendocrine cells both from colon and small bowel. Growth of C. trachomatis, 
manifested through inclusions containing both elementary bodies (EB) and reticulate 
bodies (RB) at 24h post infection could be observed for both cell lines. When EEC 
were treated with penG we observed enlarged, aberrant bacteria reminiscent of 
persistent growth forms. 
 
4.3.2 Microarray 
In order to screen host-cell gene regulation in response to C.trachomatis infection we 
used microarrays representing 30 000 human genes. We studied gene changes at the 
same time point (24 h post infection) in both active and persistent infection. Twenty-
four hours after infection represents a period of active metabolism and binary fission of 
C. trachomatis reticulate bodies within the host cell. 
 
4.3.2.1 Cell line specific responses to active and persistent infection 
We identified 66 differently transcribed genes or expressed sequence tags (ESTs) (61 
up-regulated) in active Chlamydia infected LCC-18 cells compared to non-infected and 
411 (108 up-regulated) in persistently infected LCC-18 cells compared to non-infected 
cells. Twelve differently transcribed genes (11 up-regulated) were identical for both 
active and persistent infection of LCC-18 cells. DAVID Functional Annotation Tool 
recognized 4 clusters (apoptosis, transcription regulation activity, vesicle-mediated 
transport, intrinsic to membrane). 
 
Similarly, we identified 68 differently transcribed genes or expressed sequence tags 
(ESTs) in actively infected CNDT-2 cells (58 up-regulated) and 170 differently 
transcribed genes or ESTs (120 up-regulated) in persistently infected CNDT-2 cells 
compared to non infected cells. Thirty-nine differently transcribed genes (all up-
regulated) were identical for both active and persistent infection of CNDT-2 cells. 
Genes were grouped into 8 clusters (amine biosynthesis, apoptosis, intracellular 
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organelle lumen, plasma membrane, ion-binding, transcription regulator activity, 
intracellular non-membrane-bounded organelle, amino-acid transporter activity). 
 
4.3.2.2 C. trachomatis active and persistent infection gene signatures 
Host response to infection in two different enteroendocrine cell lines in active 
chlamydial infection seemed to be similar but not identical. Only 8 differently 
transcribed genes (6 up-regulated) were identical for both CNDT-2 and LCC-18 cell 
lines but all of differently transcribed genes were grouped in the same clusters. Clusters 
consisted of genes involved in apoptosis, negative regulation of cell communication, 
ion binding, cellular protein catabolic process, cell cycle, membrane-enclosed lumen, 
cytokine activity, and vesicle mediated transport. 
 
Forty-four of differently transcribed genes (18 up-regulated and 26 down-regulated) 
were identical for both CNDT-2 and LCC-18 cells in persistent infection. Among them 
were genes involved in apoptosis, cytokine activity, growth factor activity, cell cycle, 
DNA metabolic process, intracellular organelle lumen, amine biosynthesis, 
transcription regulation activity, cell-cell signalling, regulation of phosphorylation, ion 
binding and plasma membrane. Remaining genes were involved in immune response, 
vesicle lumen, cytoplasmic vesicle, vesicle mediated transport, intrinsic to membrane 
and regulation of cell motion. Baculoviral IAP repeat-containing 3 (BIRC3) was the 
only gene that was up-regulated in the two cell lines during both active and persistent 
infection. 
 
4.3.2.3 Selected genes of interest 
Grouping of particular genes into specific functional classes is arbitrary to a certain 
degree, because some genes may be involved in several cellular functions and 
pathways. In order to study the cell-type specific response to infection, we decided to 
specifically look at the genes associated with transport and enteroendocrine function. 
We found significant differences in the gene transcription levels between persistently 
infected and non-infected cells in 10 genes coding for different solute carrier 
transporters (SLC). 
 
Moreover, we found significant differences in expression of genes related to glutamate 
transport and synthesis. (SLC1A4, SLC7A11, argininosuccinate synthetase 1 (ASS1) 
and glutamate receptor interacting protein 1 (GRIP 1)) in persistently infected cells 
compared to non-infected. We identified 5 genes related to EEC function that were 
differently transcribed in persistent infection compared to non-infected cells: 
GABARAPL1, GRIP1, DRD2, SYT5 and SYT7. 
 
We found many similarities but also many differences in response to infection probably 
due to significant differences in basal gene transcriptions (non-infected cells, data not 
shown) between the two studied lines. For example basal expressions of receptors for 
gamma-aminobutyric acid:  (GABA)A receptor, alpha 1 (GABRA1), (GABA)A 
receptor, alpha 3 (GABRA3), (GABA)A receptor, beta 2 (GABRB2) and (GABA)B 
receptor 1 (GABBR1) were significantly lower in non-infected CNDT2 than in non-
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infected LCC-18 and in contrast (GABA)A receptor-associated protein like 1 
(GAPARAPL1) expression was higher in non-infected LCC-18 cells (data not shown). 
 
4.4 SMALL BOWEL MUCOSA-ASSOCIATED MICROBIOTA IN PATIENTS 
WITH IBS AND HEALTHY CONTROLS (IV) 
4.4.1 454-sequencing of small bowel mucosa-associated microbiota 
4.4.1.1 Sequencing run 
An average number of 3837 reads per sample was obtained after processing of the raw 
data from the pyrosequencing run. The total number of reads per sample ranged from 
732 to 5870. After classification of the reads by comparison to the 16S database from 
RDP, an average of 235 reads per sample (approximately 6.3% of the total number of 
reads per sample) could not be assigned any taxonomic classification. Taxa with an 
average number of reads in the entire data set of less than 1 were excluded from further 
processing and visualization. 
 
4.4.1.2 Characterisation of small bowel microbiota 
We characterized small bowel microbiota at both phylum and taxon level. We found 
that 6 phyla (Firmicutes,  Proteobacteria, Bacteroidetes, Actinobacteria, Fusobacteria 
and Candidate division TM7) dominated in the jejunum of both controls and patients 
with IBS (Figure 3). 
 
 
Figure 3 A. Prevalence of sequences belonging to different phyla among healthy 
controls and patients with diarrhoea-predominated irritable bowel syndrome (D-IBS). 
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4.4.1.3 Principal coordinates analysis 
Principal Coordinates Analysis (PCoA) of all samples was performed in UniFrac (81). 
Clustering in UniFrac showed a rather tight cluster that contained all samples which 
indicating that samples were similar to one another. Controls and D-IBS cases were 
more dispersed, whereas C-IBS and M-IBS showed tendencies to forming their own 
two clusters in the middle of the main cluster. In conclusion, samples appeared to have 
a similar bacterial composition and did not form any distinct clusters and thus, do not 
indicate any clear differences between the four groups. 
 
4.4.1.4 Investigation of significant differences 
The three subgroups of IBS and all IBS cases were compared with the control group 
using the statistical tool “R” in search for significant differences between the controls 
and the IBS cases. No significant difference was found at either phylum or taxon level 
when comparing the controls to the other four groups. At genus level, several genera 
turned out to differ significantly between the different IBS groups and the controls. 
Ochrobactrum and Escherichia/Shigella were two of the genera differing significantly 
(p < 0.01) between the combined IBS group and controls but also between M-IBS and 
controls. However, the prevalences were very low for these genera (below 1%) and 
when plotting the abundance of them for each individual tested, it became clear that 
there was no consistent pattern of higher or lower prevalence in the different groups. 
 
 
 
Figure 3 B. Prevalence of sequences belonging to different phyla among patients with 
constipation-predominated (C-IBS) and mixed-type (M-IBS) irritable bowel syndrome. 
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4.4.1.5 Bacterial prevalence patterns 
MultiExperiment Viewer (MeV) is a tool for visualization of prevalence patterns and 
among other things also for clustering. The prevalence patterns for the characterized 
samples are all similar and a clustering of samples based on phyla abundance results in 
a random clustering with no distinct clusters based on the different groups. The 
clustering of samples based on taxa abundance indicated lower prevalence of 
unclassified Enterobacteriaceae sp. among IBS patients (C-IBS and M-IBS) than 
among controls, however the differences were not statistically significant. 
 
4.4.1.6 Shannon diversity index 
Shannon diversity indices were calculated for each of the studied groups using R. The 
variance was larger for the M-IBS group than for the other groups, showing a 
particularly a lower diversity index for some of the samples. However, the M-IBS 
group showed a larger variance for the diversity than the other groups where the sample 
with the lowest diversity index was much less diverse than the mean values of all other 
groups but was still not considered as an outlier (compared to the outlier in the control 
group). A lower number of pyrosequencing reads for these samples could be the cause 
of them showing low diversity indices (92). 
 
  25 
5 DISCUSSION 
The central part of this thesis was the investigation of the presence of Chlamydia 
antigens in small bowel biopsies in patients with a diagnosis of IBS. This has never 
been done before. The novel parts of immunofluorescence findings will be discussed 
briefly with the possible influence of Chlamydia infection on enteroendorine cells 
investigated in vitro in studies II and III followed by major findings in study IV. 
 
5.1 CHLAMYDIA TRACHOMATIS ANTIGENS IN ENTEROENDOCRINE 
CELLS AND MACROPHAGES OF THE SMALL BOWEL IN PATIENTS 
WITH SEVERE IRRITABLE BOWEL SYNDROME 
We report the novel finding of chlamydial antigens in enteroendocrine cells and 
macrophages of the small bowel mucosa in patients with severe IBS. LPS and MOMP 
antigens were detected in mucosa and l. propria of the small bowel in a large majority 
of patients with IBS, but rarely so in healthy controls. The odds ratio for mucosal 
Chlamydia LPS being indicative for presence of IBS is much higher than any 
previously described pathogenetic marker in IBS (31). These findings raise several 
questions: 
 
5.1.1 Do observed immunofluorescence findings represent presence of 
bacterial antigens? 
The specificity of the LPS antibody is important in this respect. There is a risk that 
antibodies may give rise to unspecific binding but such binding should not differ 
between patients and controls. We therefore think that unspecific binding is an unlikely 
explanation for our findings. It has previously been shown that this monoclonal anti-
LPS antibody does not bind to environmental Chlamydiae (93, 94). The genus-specific 
LPS epitope is not shared by other known gram-negative bacteria and monoclonal 
antibodies do not bind LPS of those organisms (95). Thus, positive staining of LPS can 
be considered as a marker of past or present Chlamydia infection. 
 
We used different techniques to visualize Chlamydia LPS. In addition to 
immunofluorescence with a FITC-conjugated monoclonal antibody, we used a 
polyclonal antibody to Chlamydia LPS and the standard streptavidin-biotin technique 
for light microscopy. The latter technique also showed presence of antigen in the same 
cell types. We used Western blot on new biopsies from a limited number of patients 
and confirmed that Chlamydia LPS was present in the tissue samples from these 
patients. These findings further support the hypothesis that observed antigens have a 
bacterial origin. 
 
5.1.2 What is the identity of the species involved? 
We used a genus-specific antibody to Chlamydia LPS and species-specific antibodies 
to C. pneumoniae and C. trachomatis MOMP. Since we found positive staining for C. 
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trachomatis MOMP in 79% of Chlamydia LPS-positive biopsies and none of them was 
positive for C. pneumoniae we hypothesized that the origin of these antigens was a past 
or present infection with C. trachomatis. Also, since we found positivity for C. 
trachomatis antigens using two different monoclonal antibodies, one for LPS and one 
for MOMP, cross-reaction with another, similar species, is unlikely but not fully 
excluded. 
 
5.1.3 Do observed antigens represent an ongoing infection or not? 
We investigated archived biopsy material from the small bowel and this puts certain 
limits on our ability to ascertain the underlying cause for observed findings as well as 
their specificity. In order to confirm and strengthen our immunohistochemical findings 
we used antibodies to different antigens and also different methods of visualisation. In a 
limited number of cases we had the opportunity to take new biopsies for more 
advanced analyses using molecular biology techniques, proteomics and electron 
microscopy. Whereas electron microscopy showed presence of Chlamydia-like 
organisms in the cytoplasm of enteroendocrine cells, similar to those described in 
persistent C. trachomatis infection (96), we were unable to detect chlamydial DNA in a 
small number of patients using standard extraction and amplification protocols. It is 
possible that the standard methods we used for nucleic acid retrieval were inadequate 
for the detection of a persistent infection (97). Another explanation for the 
contradictory results could be that chlamydial antigens were remainders of a past, but 
no longer present infection (98). The latter seems unlikely in light of the long-term 
presence of C. trachomatis antigens observed in several of our patients. Long-term 
presence of antigens is more likely to be attributable to replicating Chlamydiae residing 
in the diseased tissue (99). At present, however, we cannot determine if patients with 
severe IBS have an ongoing intestinal infection with C. trachomatis or not. Neither can 
we explain the presence of inflammation in myenteric ganglia or neuropathy by the 
finding of chlamydial antigens in enteroendocrine cells. 
 
5.2 IN VITRO INTERACTION BETWEEN EEC AND CHLAMYDIA 
TRACHOMATIS  
Enteroendocrine cells play a pivotal role in the control of gut motility and secretion and 
increased numbers of enteroendocrine cells have been detected in patients that 
developed IBS after an acute gastroenteritis (100). It is unknown if infection alters the 
function of enteroendocrine cells in man but animal experiments using different models 
of enteric infection have shown pronounced changes in both numbers of 
enteroendocrine cells and their function (101, 102). Serotonin-producing 
enteroendocrine cells may present an ideal location for Chlamydia due to their 
abundance of tryptophan. Tryptophan is required for normal development in 
Chlamydia species and tryptophan metabolism has been implicated in Chlamydia 
persistence and tissue tropism (103). 
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Studies II and III showed that it is possible to infect EEC from both small bowel 
(CNDT-2 cell line) and large bowel (LCC-18 cell line) with C. trachomatis, which are 
able to grow and multiply within EEC. Furthermore, in both cell lines a state of 
persistent infection with C. trachomatis could be induced. We think the latter is more 
important since it may mimic the situation in patients with IBS. 
 
Study II is the first to show that the presence of C. trachomatis alters the cellular 
distributions of serotonin and CgA in vitro. Both serotonin and CgA are important for 
immune activation and gut inflammation in vivo and several serotonergic receptors 
have been characterized in lymphocytes, monocytes, macrophages and dendritic cells 
(104). Serotonin has been shown to activate immune cells, which are responsible for 
the production of proinflammatory mediators. Consequently, a manipulation of the 
serotonin system could possibly modulate responses to gut inflammation (105). CgA on 
the other hand has antimicrobial activity (106) and exhibits both proinflammatory and 
anti-inflammatory functions (105). 
 
Altered protein distributions together with down-regulation of the vesicular monoamine 
transporter VMAT1 suggest bacterial influence on vesicular transport since the 
expressions of genes associated with serotonin synthesis (TPH1) and release (TRPA1) 
were not impaired. At this stage, it is not clear whether the altered serotonin and CgA 
distribution in C. trachomatis infected EEC is induced by the bacteria themselves or is 
part of the innate immunity response via TLR4 up-regulation. Kidd et al. (107) reported 
increased LPS-induced serotonin secretion in EEC derived from patients with Crohn's 
disease. TLR4 stimulation with its agonist LPS also caused the release of human β-
defensin-2 (HBD-2) from EEC (51) and elevated HBD-2 levels have recently been 
found in patients with IBS (108). 
 
Study III is the first to describe Chlamydia-induced transcriptome changes in 
enteroendocrine cells. Studying cell-type specific response to infection we found 
significant differences in the gene transcription levels between persistently infected and 
non-infected cells in 10 genes coding for different solute carrier transporters (SLC) and 
we identified 5 genes related to endocrine function that were differently transcribed in 
persistent infection compared to non- infected cells: GABAA receptor-associated 
protein like 1 (GABARAPL1), glutamate receptor interacting protein 1 (GRIP1), D2 
subtype of the dopamine receptor (DRD2), synaptotagmin 5 (SYT5) and 
synaptotagmin 7  (SYT7). Transporters are the gatekeepers for all cells and organelles, 
controlling uptake and efflux of crucial compounds such as sugars, amino acids, 
nucleotides, inorganic ions and drugs. The SLC family include genes encoding passive 
transporters, ion coupled transporters and exchangers (109).  
 
Although the majority of investigators in this area have focused on alterations to 5-HT 
signalling during GI inflammation study III shows the impact of Chlamydia infection 
on genes encoded proteins associated with neurotransmitters (GABARAPL1, GRIP, 
DRD2) and genes encoding synaptotagmins (proteins responsible for neurotransmitters 
exocytosis from vesicles) (110). EEC, being mucosal sensory transducers, are the part 
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of enteric nervous system (ENS) together with afferent neurons, interneurons and 
motor neurons (52). Obtained results support the thesis that inflammatory effects on the 
ENS contribute to altered function during GI inflammation. It appears that changes in 
enteroendocrine cells and the effectors of their neuroactive substances are adaptive 
responses to inflammatory insults. Studies II and III reveal potentially important 
Chlamydia-induced alterations in EEC signalling.  
 
5.3 SMALL BOWEL MICROBIOTA 
Several studies have indicated that colonic microbial flora may exhibit important 
differences between patients with certain subtypes of IBS and healthy controls. Little is 
known about the microbial flora of the small bowel. In Study IV we used pyrotag 
sequencing in order to deeply explore and compare the composition of small bowel 
mucosa-associated microbiota between patients with IBS and healthy controls, 
something that has never been done before. We detected representatives of several 
genera with a predominance of Firmicutes. On the taxon level Streptococcus spp., 
Veillonella spp., Prevotella spp., unclassified Pasteurellaceae spp., Rothia spp., 
Haemophilus spp. and unclassified Enterobacteriaceae spp. were the dominating 
species. 454-barcoded pyrosequencing is a very powerful method to explore the 
diversity within human gut ecosystems but it also has some limitations. One of them is 
the inability to distinguish between live and dead bacteria. Using jejunal biopsies 
instead of jejunal fluid we analyzed mucosa associated bacteria, thus diminishing the 
possibility of sequencing dead bacteria passing gastrointestinal tract. The mucosa-
associated bacteria are of particular interest since they, generally speaking, are more 
likely to have a direct effect on the host through the mucosal layer than the bacteria 
only passing through the intestinal tract.  
 
We cannot exclude the contamination from oral or esophageal flora although the 
probability is very low. We rinsed Watson capsules in sterile NaCl-solution before 
opening them and our method for DNA extraction was designed to extract only 
mucosa-associated flora. However, we found similarities at both phylum and genus 
levels with previously described microbiota from the distal esophagus (111). The same 
6 phyla (Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria, and 
Candidate division TM7) although differing in relative proportions were represented in 
both the distal esophagus and in our biopsies from the jejunum. Streptococcus, 
Prevotella and Veillonella were the most prevalent genera in both esophagus and 
jejunum. 
 
We found bacteria belonging to the genus Chlamydia (unclassified Parachlamydia) in 
only 5 patients (data not shown). This is perhaps surprising in view of our previous 
studies but there are several explanations for a negative result: 
i. Chlamydia is an obligate intracellular pathogen and in study I Chlamydia 
LPS was localised to EEC at the level of the crypts not at the villous 
surface of the mucosa;  
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ii. We used a method for DNA extraction that was designed to extract 
mucosa-associated flora, not intracellular bacteria; and  
iii. Barcoded pyrosequencing is a method to study the diversity of microbiota, 
not to detect specific bacteria. The amount of Chlamydia DNA available 
for extraction and 454-sequencing may have been below the detection level 
of the method.  
We found no major difference in small bowel microbiota between patients with IBS 
and healthy controls. Subject-to-subject variation was large among both patients and 
controls. Our results correlate with some previous studies describing faecal microbiota 
in IBS patients and healthy controls (112-114). Our study does not support a role of 
SIBO in IBS. The relationship between SIBO and IBS is highly inconsistent among 
studies (115). In a recently published study Yu et al. (116) demonstrated that breath 
testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients 
with IBS. 
 
From an ecological perspective, abnormal variation likely reflects a loss of 
homeostasis, in which the microbial community is unable to maintain its normal 
structure. A high degree of variation is typical for disturbed and re-establishing 
communities undergoing succession, while the loss of variation is usually associated 
with a loss of diversity and outgrowth of certain taxa. Our results suggest that the 
luminal flora is probably not a host factor for the development of IBS. 
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6 CONCLUSIONS 
Study I introduced the novel concept of a bacterial aetiology in cases of severe IBS. 
Our results suggest that C. trachomatis may be involved in the pathogenesis in IBS. 
 
The findings from Study II and Study III support the hypothesis that C. trachomatis 
may have a role in IBS by showing in vitro that enteroendocrine cells from both the 
small bowel and the large bowel can be infected by C. trachomatis. In both cell lines a 
state of persistent infection with C. trachomatis can be induced.  
 
Studies II and III give new insights into the cellular events that take place during 
Chlamydia infection of enteroendocrine cells. The results of Study II and Study III 
provide in vitro evidence that an infection of enteroendocrine cells in vivo can lead to 
disturbances in the regulation of the gut function. 
 
In Study IV we found no major difference in small bowel microbiota between patients 
with IBS and healthy controls, and this suggests that the luminal flora is probably not a 
host factor for the development of IBS. 
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7 SAMMANFATTNING PÅ SVENSKA 
Syftet med de arbeten som redovisas i denna avhandling var att ta reda på om bakterier 
har någon betydelse för uppkomsten av irritabel tarm (eng. IBS = irritable bowel 
syndrome). Irritabel tarm är en av våra största folksjukdomar och man räknar med att 
ungefär 15 % av befolkningen har någon variant av denna sjukdom. Orsaken eller 
orsakerna till IBS är inte kända men sjukdomen har länge betraktats som 
psykosomatisk. Modern forskning har emellertid visat att patienter med IBS har 
störningar i såväl de immunologiska som de enteroendokrina reglersystemen i tarmen. 
Det immunologiska systemet reglerar vårt försvar mot olika mikroorganismer samtidigt 
som det tillåter närvaron av stora mängder bakterier, virus och parasiter i vår mag-
tarmkanal. Det enteroendokrina systemet utgörs av ett stort antal celler i mag-
tarmkanalens slemhinna som känner av vad vi har ätit och som genom utsöndring av 
särskilda signalsubstanser kan styra tarmens motorik och enzymsekretion så att 
matsmältning och näringsupptag blir så effektivt som möjligt. Vävnadsprover från 
tunntarmen undersöktes med hjälp av immunofluorescens avseende förekomsten av 
klamydia-specifik lipopolysackarid (LPS) hos 65 patienter med IBS och 42 friska 
försökspersoner. LPS påvisades i enteroendokrina celler och/eller makrofager hos 
58/65 (89 %) patienter men endast 6/42 (14 %) kontroller. Ytterligare undersökning 
visade att 79 % av de LPS-positiva proverna också var positiva i immunfärgning för 
membranproteinet MOMP från bakterien Chlamydia trachomatis. Dessa fynd 
indikerade att en persistent infektion med C. trachomatis i tunntarmen kunde ha 
betydelse för uppkomsten av IBS. Fyndet av bakteriella antigener i enteroendokrina 
celler talade för en tidigare icke känd celltropism för C. trachomatis. För att validera 
detta fynd genomfördes en serie in vitro experiment med enteroendokrina cellinjer. Två 
olika cellinjer, LCC-18, från en endokrin colontumör, och CNDT-2 från en 
tunntarmscarcinoid studerades före och efter infektion med C. trachomatis. Båda 
cellinjerna kunde infekteras med C. trachomatis och persistent infektion kunde 
induceras med hjälp av penicillin G. Infektionen ledde till en tydlig omfördelning 
intracellulärt av proteinet chromogranin A och signalsubstansen serotonin så att dessa i 
infekterade celler huvudsakligen återfanns i de bakteriella inklusionerna i stället för i 
cytoplasman. Genuttrycket för en lång rad gener uppreglerades eller nedreglerades i 
infekterade celler. Bland celltypsspecifika förändringar av genuttryck märktes 
signifikant förändring av genuttrycket för 10 transportproteiner inom gruppen SLC 
(solute carrier transporters) och 5 gener som har med cellernas endokrina funktion att 
göra (GABARAPL1, GRIP1, DRD2, SYT5 and SYT7). Slutligen studerades den 
mucosa-associerade bakteriefloran in tunntarmens övre del hos patienter med IBS och 
friska kontroller. Florans sammansättning analyserades med 454-pyrosekvensiering. 
Inga betydande skillnader hittades mellan patienter och kontroller. Sammanfattningsvis 
pekar denna avhandling på möjligheten att IBS orsakas av en persistent klamydia-
infektion i tarmen. Studier av cellinjer visar att sådan infektion leder till uttalade 
förändringar i enteroendokrin funktion som kan tänkas vara en del av förklaringen till 
många av de symtom patienter med IBS lider av. Den luminala floran däremot 
förefaller inte vara av betydelse för uppkomsten av IBS. 
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